Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain

BACKGROUND: HPV cervical cancer screening (CCS) must use validated HPV tests based on the molecular detection of either viral mRNA (Aptima HPV Assay—AHPV) or DNA. AHPV has demonstrated the same cross-sectional and longitudinal sensitivity for the detection of HSIL/CIN2+ lesions but with greater spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibáñez, R., Mareque, M., Granados, R., Andía, D., García-Rojo, M., Quílez, J. C., Oyagüez, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074415/
https://www.ncbi.nlm.nih.gov/pubmed/33902553
http://dx.doi.org/10.1186/s12905-021-01310-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074415/
https://www.ncbi.nlm.nih.gov/pubmed/33902553
http://dx.doi.org/10.1186/s12905-021-01310-8

Ejemplares similares